指南与共识神经肿瘤

儿童低级别胶质瘤MAPK抑制治疗中的耐药、反弹与复发再生长模式:改良德尔菲法构建国际共识定义——国际儿童低级别胶质瘤联盟

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
指南 / 共识 · Neuro Oncol · 2024-01-01

儿童低级别胶质瘤(pLGG)在无法治愈性切除时呈慢性病程,多数存在RAS/MAPK通路激活,BRAF与MEK联合抑制已获监管批准用于BRAFV600E突变pLGG。国际儿童低级别胶质瘤联盟成立R3工作组,采用改良德尔菲法制定针对靶向治疗中耐药、停药后反弹(停药3个月内快速再生长)及复发等再生长模式的共识定义与推荐。

要点

  • pLGG无法治愈性切除时呈慢性病程,总体生存率高但许多患者有显著且可能终身的并发症。
  • 多数pLGG存在RAS/MAPK通路激活突变,BRAF与MEK联合抑制已获监管批准用于BRAFV600E突变pLGG。
  • 靶向治疗中可因耐药再生长,停药后可复发,部分患者停药3个月内出现快速反弹生长;R3工作组以改良德尔菲法制定共识定义与推荐。

核心结论

  • 国际儿童低级别胶质瘤联盟R3工作组采用改良德尔菲法,针对pLGG靶向治疗中的耐药、反弹与复发再生长模式制定共识定义与推荐。

研究设计与样本

  • 国际儿童低级别胶质瘤联盟(全球医生与科学家组成的团体)成立耐药、反弹与复发(R3)工作组,采用改良德尔菲法制定共识。

主要发现

  • pLGG无法治愈性切除时自然史为慢性疾病,有肿瘤稳定期和进展发作期,总体生存率高但许多患者有显著且可能终身的并发症。
  • 多数pLGG因突变事件存在RAS/MAPK通路激活,导致临床试验中使用分子靶向治疗,近期BRAF与MEK联合抑制获监管批准用于BRAFV600E突变pLGG。
  • 尽管活性令人鼓舞,治疗中可因耐药出现肿瘤再生长,停药后可作为肿瘤复发出现,部分患者报告为停药后3个月内快速反弹生长。
  • 这些再生长模式的定义在pLGG中尚未得到很好描述。

关键数值与推荐

  • 原文未报告具体推荐条款或推荐等级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection is not possible, is one of a chronic disease with periods of tumor stability and episodes of tumor progression. While there is a high overall survival rate, many patients experience significant and potentially lifelong morbidities. The majority of pLGGs have an underlying activation of the RAS/MAPK pathway due to mutational events, leading to the use of molecularly targeted therapies in clinical trials, with recent regulatory approval for the combination of BRAF and MEK inhibition for BRAFV600E mutated pLGG. Despite encouraging activity, tumor regrowth can occur during therapy due to drug resistance, off treatment as tumor recurrence, or as reported in some patients as a rapid rebound growth within 3 months of discontinuing targeted therapy. Definitions of these patterns of regrowth have not been well described in pLGG. For this reason, the International Pediatric Low-Grade Glioma Coalition, a global group of physicians and scientists, formed the Resistance, Rebound, and Recurrence (R3) working group to study resistance, rebound, and recurrence. A modified Delphi approach was undertaken to produce consensus-based definitions and recommendations for regrowth patterns in pLGG with specific reference to targeted therapies.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. O'Hare P, Cooney T, de Blank P, et al. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition. Neuro Oncol. 2024. PMID: 38743009. doi:10.1093/neuonc/noae074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。